University of Minnesota sues Gilead over $20 billion Hepatitis C drug business
The University of Minnesota is suing Gilead Sciences Inc., alleging the pharmaceuticals company's lucrative Hepatitis C drugs infringe on a university patent.
In a lawsuit filed in Minnesota's U.S. District Court Monday, the university claimed its intellectual property covers Gilead products that contain the drug sofosbuvir, including those sold under the brand names Sovaldi and Harvoni. Those Hepatitis C treatments have generated more than $20 billion in revenue for Foster City, Calif.-based Gilead.
Continue reading...
No comments:
Post a Comment